Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders

22 Jul 2016

Abstract excerpt

INTRODUCTION: Proteasome inhibitors have garnered interest as novel chemotherapeutic agents based on their ability to inhibit the growth of cancer cells by altering the balance of intracellular proteins. Initial clinical trials of this drug class focused on bortezomib, a reversible inhibitor of the 20S proteasome, with promising results for the treatment of adult hematologic malignancies, including multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27447436
DOI: 10.1080/17474086.2016.1216311

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disordersPMID 27447436Read ↗

Novel Proteasome Inhibitors to Overcome Bortezomib ResistanceSemantic proximity Read ↗

The role of proteasomes in tumorigenesisSemantic proximity Read ↗

Emerging therapies targeting the ubiquitin proteasome system in cancerSemantic proximity Read ↗

Proteasome as an Emerging Therapeutic Target in CancerSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

The role of the ubiquitin proteasome system in lymphomaSemantic proximity Read ↗

The Proteasome in Cancer Biology and TreatmentSemantic proximity Read ↗

A Single Institution Experience of Bortezomib for GVHD in a Pediatric HSCT PopulationSemantic proximity Read ↗

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cellsSemantic proximity Read ↗

Functions of the proteasome: from protein degradation and immune surveillance to cancer therapySemantic proximity Read ↗

Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic InterventionSemantic proximity Read ↗

26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.